Rapport Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
RAPP$26.07+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share data)
| March 31,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $78,056 | $52,645 |
| Accounts receivable | 58 | — |
| Short-term investments | 398,726 | 437,894 |
| Restricted cash | 105 | 105 |
| Prepaid expenses and other current assets | 7,750 | 7,917 |
| Total current assets | 484,695 | 498,561 |
| Property and equipment, net | 2,518 | 2,976 |
| Operating lease right of use asset, net | 9,327 | 9,909 |
| Other assets | 1,057 | 985 |
| Total assets | $497,597 | $512,431 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $6,561 | $4,190 |
| Accrued expenses and other current liabilities | 8,721 | 12,104 |
| Operating lease liability | 2,615 | 2,755 |
| Total current liabilities | 17,897 | 19,049 |
| Operating lease liability, net of current portion | 8,188 | 8,729 |
| Total liabilities | 26,085 | 27,778 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity | ||
| Undesignated preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively; zero shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 47,807,453 shares and 47,772,567 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 48 | 48 |
| Additional paid-in capital | 727,054 | 719,287 |
| Accumulated other comprehensive income (loss) | (505) | 546 |
| Accumulated deficit | (255,085) | (235,228) |
| Total stockholders’ equity | 471,512 | 484,653 |
| Total liabilities and stockholders’ equity | $497,597 | $512,431 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.